Chapter 69: SLE Flashcards
A 35-year-old woman of African American descent presents to the clinic with complaints of fatigue, joint pain, and a rash on her cheeks and nose. She reports that these symptoms have been recurring for several years, with periods of improvement and worsening. Laboratory tests reveal anemia and elevated antinuclear antibodies (ANA). What is the most likely diagnosis for this patient?
a. Rheumatoid arthritis
b. Systemic lupus erythematosus (SLE)
c. Osteoarthritis
d. Fibromyalgia
b. Systemic lupus erythematosus (SLE)
Rationale: The patient’s symptoms (fatigue, joint pain, and characteristic malar rash) along with laboratory findings (anemia and elevated ANA) are indicative of SLE. SLE is known for its chronic, unpredictable course with periods of remission and exacerbation, and it more commonly affects women, particularly those of African American descent.
Which of the following systems are commonly affected by systemic lupus erythematosus (SLE)?
a. Cardiovascular, endocrine, and gastrointestinal
b. Skin, joints, and serous membranes
c. Muscular, respiratory, and reproductive
d. Skeletal, digestive, and urinary
b. Skin, joints, and serous membranes
Rationale: SLE typically affects the skin, joints, and serous membranes (pleura, pericardium). It is a multisystem inflammatory autoimmune disease, meaning it can affect multiple organ systems, but the skin, joints, and serous membranes are commonly involved.
What factors contribute to the development of systemic lupus erythematosus (SLE)? (SATA)
a. Genetic factors
b. Hormonal factors
c. Environmental factors
d. Immune factors
all of the choices are correct
Rationale: SLE is a complex disorder of multifactorial origin, resulting from interactions among genetic, hormonal, environmental, and immune factors. Each of these factors plays a role in the development and progression of the disease.
Which population is more likely to develop systemic lupus erythematosus (SLE) compared to Whites?
a. European Americans
b. Middle Eastern Americans
c. Native Americans
d. Pacific Islanders
c. Native Americans
Rationale: SLE is more prevalent in certain ethnic groups, including Blacks, Asian Americans, Hispanics, Native Americans, and Pacific Islanders, compared to Whites. These populations are more likely to develop SLE.
A 28-year-old Hispanic woman is diagnosed with systemic lupus erythematosus (SLE). She asks about the typical age range when SLE symptoms begin to appear. What is the appropriate response?
a. Between 10 to 30 years
b. Between 15 to 45 years
c. Between 20 to 50 years
d. Between 25 to 55 years
b. Between 15 to 45 years
Rationale: Most people with SLE develop the disease between ages 15 to 45 years. This age range is typical for the onset of SLE symptoms.
Which of the following systems are often affected by systemic lupus erythematosus (SLE)? (SATA)
a. Renal system
b. Hematologic system
c. Neurologic system
d. Endocrine system
a. Renal system
b. Hematologic system
c. Neurologic system
Rationale: SLE often affects the renal, hematologic, and neurologic systems. These systems can experience various complications and manifestations due to the autoimmune nature of the disease.
A 30-year-old woman presents to the clinic with complaints of fatigue, joint pain, and photosensitivity. She has a family history of systemic lupus erythematosus (SLE). Genetic testing reveals the presence of HLA-DR2 and HLA-DR3 genes. What role do these genes play in the development of SLE?
a. They directly cause SLE.
b. They are protective against SLE.
c. They have no known association with SLE.
d. They are associated with an increased risk of developing SLE.
d. They are associated with an increased risk of developing SLE.
Rationale: Multiple genes from the HLA complex, including HLA-DR2 and HLA-DR3, are associated with an increased risk of developing SLE. These genetic factors contribute to the susceptibility to the disease.
Which hormonal factors are known to play a role in the onset or worsening of systemic lupus erythematosus (SLE)?
a. Start of menses, oral contraceptive use, and pregnancy
b. Menopause and hormone replacement therapy
c. Androgen therapy
d. Corticosteroid use
a. Start of menses, oral contraceptive use, and pregnancy
Rationale: Hormones play a significant role in SLE. The onset or worsening of disease symptoms may occur after the start of menses, with oral contraceptive use, and during and after pregnancy.
Which environmental factors can contribute to the development of systemic lupus erythematosus (SLE)? (SATA)
a. Sun or ultraviolet light exposure
b. Exposure to silica dust
c. Dietary habits
d. Exposure to some chemicals and toxins
a. Sun or ultraviolet light exposure
b. Exposure to silica dust
d. Exposure to some chemicals and toxins
Rationale: Environmental factors that contribute to SLE include sun or ultraviolet light exposure, exposure to silica dust, and exposure to some chemicals and toxins. These factors can trigger or exacerbate the disease.
Which infection is known to stimulate immune hyperactivity and potentially contribute to systemic lupus erythematosus (SLE)?
a. Hepatitis B virus
b. Epstein Barr virus
c. Human papillomavirus (HPV)
d. Influenza virus
b. Epstein Barr virus
Rationale: Infections, including the Epstein Barr virus, may stimulate immune hyperactivity and potentially contribute to the development of SLE.
A patient with a long history of tetracycline use presents with symptoms suggestive of systemic lupus erythematosus (SLE). What type of SLE might this patient be experiencing?
a. Drug-induced SLE
b. Genetic SLE
c. Environmental SLE
d. Idiopathic SLE
a. Drug-induced SLE
Rationale: Drug-induced SLE can occur months to years after continuous therapy with a causative drug, such as tetracycline. This condition should not be confused with drug side effects.
Which of the following autoantibodies are commonly made by the body in systemic lupus erythematosus (SLE)?
a. Antibodies against viral antigens
b. Antibodies against bacterial proteins
c. Antibodies against dietary proteins
d. Antibodies against nucleic acids
d. Antibodies against nucleic acids
Rationale: In SLE, the body makes various autoantibodies against nucleic acids, such as single- and double-stranded DNA, as well as against erythrocytes, coagulation proteins, lymphocytes, platelets, and many other self-proteins.
What factors are involved in the autoimmune reactions in systemic lupus erythematosus (SLE)? (SATA)
a. Antinuclear antibodies (ANA)
b. Antibodies against viral proteins
c. B and T cell activation
d. Antibodies against dietary antigens
a. Antinuclear antibodies (ANA)
c. B and T cell activation
Rationale: Autoimmune reactions in SLE involve antinuclear antibodies (ANA) that are directed against elements of the cell nucleus, especially DNA. Overaggressive autoimmune responses are related to the activation of B and T cells.
In which systems do circulating immune complexes with antibodies against DNA commonly deposit in systemic lupus erythematosus (SLE)?
a. Muscular and endocrine systems
b. Digestive and respiratory systems
c. Kidneys, heart, skin, brain, and joints
d. Reproductive and urinary systems
c. Kidneys, heart, skin, brain, and joints
Rationale: Circulating immune complexes with antibodies against DNA are deposited in the basement membranes of capillaries in the kidneys, heart, skin, brain, and joints. These complexes trigger inflammation and tissue destruction.
A 25-year-old woman presents with fatigue, joint pain, and a malar rash. Laboratory tests reveal the presence of antinuclear antibodies (ANA). What is the role of these antibodies in systemic lupus erythematosus (SLE)?
a. They target dietary proteins.
b. They are directed against elements of the cell nucleus, especially DNA.
c. They are directed against viral antigens.
d. They target bacterial proteins.
b. They are directed against elements of the cell nucleus, especially DNA.
Rationale: Antinuclear antibodies (ANA) are directed against elements of the cell nucleus, especially DNA, in SLE. These antibodies play a significant role in the autoimmune reactions associated with the disease.
Which type of hypersensitivity response is systemic lupus erythematosus (SLE) classified as?
a. Type I hypersensitivity
b. Type II hypersensitivity
c. Type III hypersensitivity
d. Type IV hypersensitivity
c. Type III hypersensitivity
Rationale: SLE is classified as a type III hypersensitivity response. This type of hypersensitivity involves the formation of immune complexes that trigger inflammation and tissue damage.
What are the potential triggers for drug-induced systemic lupus erythematosus (SLE)? (SATA)
a. Sulfa drugs
b. Diuretics
c. Tetracycline
d. Penicillin
all of the choices are correct
Rationale: Drug triggers for SLE include those that make a person more sensitive to the sun (e.g., sulfa drugs, diuretics, tetracycline) and penicillin or similar antibiotics. These drugs can contribute to the development of drug-induced SLE.
A patient with SLE is found to have immune complexes deposited in the kidneys. What is the primary consequence of this deposition?
a. Inflammation and tissue destruction
b. Kidney stones
c. Increased urine output
d. Decreased kidney function
a. Inflammation and tissue destruction
Rationale: The deposition of immune complexes in the kidneys triggers inflammation that causes tissue destruction. This can lead to decreased kidney function and other complications.
A 40-year-old patient presents with signs of systemic lupus erythematosus (SLE) and reports long-term exposure to silica dust in an industrial setting. What role might silica dust have played in the development of SLE in this patient?
a. Silica dust acts as a genetic factor.
b. Silica dust acts as a hormonal factor.
c. Silica dust is a known environmental trigger for SLE.
d. Silica dust has no known association with SLE.
c. Silica dust is a known environmental trigger for SLE.
Rationale: Exposure to silica dust in agricultural or industrial settings is a known environmental factor that can contribute to the development of SLE.
A 25-year-old woman presents with fatigue, fever, weight loss, joint pain, and a rash. She is diagnosed with systemic lupus erythematosus (SLE). The patient asks what body systems and tissues could potentially be affected by SLE. What is the best response?
a. Only the skin and joints
b. Only the kidneys and nervous tissue
c. Any organ and tissue, including skin, muscle, lungs, heart, nervous tissue, and kidneys
d. Only the cardiovascular and respiratory systems
c. Any organ and tissue, including skin, muscle, lungs, heart, nervous tissue, and kidneys
Rationale: SLE is a multisystem autoimmune disease that can affect any organ or tissue. Commonly involved tissues are the skin and muscle, lining of the lungs, heart, nervous tissue, and kidneys. General symptoms such as fever, weight loss, joint pain, and fatigue may precede exacerbations.
Which of the following statements is true regarding the progression of systemic lupus erythematosus (SLE)?
a. SLE follows a predictable pattern of progression
b. SLE is exclusively a mild disorder
c. SLE ranges from a mild disorder to a rapidly progressive disease
d. SLE only affects the skin and joints
c. SLE ranges from a mild disorder to a rapidly progressive disease
Rationale: The severity of SLE varies widely. It can range from a mild disorder to a rapidly progressive disease affecting many body systems. There is no characteristic pattern in the progression of SLE.
Which general symptoms may precede worsened disease activity in patients with systemic lupus erythematosus (SLE)? (SATA)
a. Fever
b. Weight loss
c. Joint pain
d. Fatigue
all of the choices are correct
Rationale: General symptoms that may precede worsened disease activity in SLE include fever, weight loss, joint pain, and fatigue. These symptoms can indicate a flare or exacerbation of the disease.
Which of the following tissues are commonly involved in systemic lupus erythematosus (SLE)?
a. Skin, muscle, lungs, heart, nervous tissue, and kidneys
b. Eyes, ears, liver, and pancreas
c. Teeth, nails, hair, and gastrointestinal tract
d. Bones, cartilage, spleen, and lymph nodes
a. Skin, muscle, lungs, heart, nervous tissue, and kidneys
Which type of skin lesion is most likely to develop in patients with chronic cutaneous lupus erythematosus (CCLE)?
a. Vesicular lesions
b. Discoid lesions
c. Pustular lesions
d. Bullous lesions
b. Discoid lesions
Rationale: Patients with CCLE commonly have discoid lesions, which are round and coin-shaped. These lesions typically appear on the scalp and face.
A patient with systemic lupus erythematosus (SLE) presents with a red, ring-shaped lesion on their back. The lesion does not scar or itch, and it is not thick and scaly. What type of lupus is this patient most likely experiencing?
a. Subacute cutaneous lupus erythematosus (SCLE)
b. Chronic cutaneous lupus erythematosus (CCLE)
c. Acute cutaneous lupus erythematosus
d. Drug-induced lupus erythematosus
a. Subacute cutaneous lupus erythematosus (SCLE)
Rationale: SCLE is characterized by red, ring-shaped lesions that do not scar or itch and are not thick and scaly. These features match the description provided for the patient.
Which of the following are common skin manifestations in systemic lupus erythematosus (SLE)? (SATA)
a. Malar rash
b. Alopecia
c. Oral ulcers
d. Thick, scaly lesions
a. Malar rash
b. Alopecia
c. Oral ulcers
Rationale: Common skin manifestations in SLE include the malar rash (butterfly rash), alopecia, and oral ulcers. Thick, scaly lesions are not typical of SLE.
What percentage of patients with chronic cutaneous lupus erythematosus (CCLE) later develop lupus in other organ systems?
a. 5%
b. 10%
c. 20%
d. 25%
b. 10%
Rationale: About 10% of patients with CCLE later develop lupus in other organ systems.
A 26-year-old woman with systemic lupus erythematosus (SLE) reports experiencing hair loss. She wants to know if her hair will grow back. What is the best response?
a. “Your hair loss is permanent and will not grow back.”
b. “Hair loss can occur in SLE, but it may grow back during remission.”
c. “You will need medication to help your hair grow back.”
d. “Hair loss is uncommon in SLE, so it may be due to another cause.”
b. “Hair loss can occur in SLE, but it may grow back during remission.”
Rationale: Alopecia is common in SLE, and hair may grow back during remission. However, hair loss may be permanent over lesions.
What is the most common form of acute cutaneous lupus erythematosus?
a. Discoid lesions
b. Vesicular lesions
c. Butterfly rash over the cheeks and bridge of the nose
d. Bullous lesions
c. Butterfly rash over the cheeks and bridge of the nose
Rationale: The most common form of acute cutaneous lupus erythematosus is the butterfly rash (malar rash) over the cheeks and bridge of the nose, which looks like a sunburn.
Which factors can contribute to severe skin reactions in systemic lupus erythematosus (SLE)? (SATA)
a. Sun exposure
b. Genetic predisposition
c. Stress
d. Penicillin use
a. Sun exposure
c. Stress
d. Penicillin use
Rationale: Severe skin reactions in SLE can be triggered by sun exposure, stress, and the use of certain drugs such as penicillin. Genetic predisposition, while a contributing factor to SLE in general, is not specifically linked to severe skin reactions.
A patient with systemic lupus erythematosus (SLE) presents with dry, scaly, and atrophied scalp along with hair loss. What is the most likely cause of these symptoms?
a. Psoriasis
b. Chronic cutaneous lupus erythematosus (CCLE)
c. Tinea capitis
d. Seborrheic dermatitis
b. Chronic cutaneous lupus erythematosus (CCLE)
Rationale: The symptoms of a dry, scaly, and atrophied scalp along with hair loss are consistent with chronic cutaneous lupus erythematosus (CCLE).
Which of the following symptoms is often the first sign of arthritis in patients with systemic lupus erythematosus (SLE)?
a. Erythema
b. Pain in multiple joints with morning stiffness
c. Muscle weakness
d. Fever
b. Pain in multiple joints with morning stiffness
Rationale: Pain in multiple joints (polyarthralgia) with morning stiffness is often the first symptom of arthritis in patients with SLE. This symptom may precede the onset of multisystem disease by many years.
What are some common deformities associated with SLE-related arthritis? (SATA)
a. Swan neck deformity of the fingers
b. Ulnar deviation
c. Subluxation with joint laxity
d. Kyphosis
a. Swan neck deformity of the fingers
b. Ulnar deviation
c. Subluxation with joint laxity
Rationale: Common deformities associated with SLE-related arthritis include swan neck deformity of the fingers, ulnar deviation, and subluxation with joint laxity. Kyphosis is not typically associated with SLE-related arthritis.
What type of arthritis is typically seen in patients with systemic lupus erythematosus (SLE)?
a. Erosive arthritis
b. Nonerosive arthritis
c. Septic arthritis
d. Osteoarthritis
b. Nonerosive arthritis
Rationale: SLE-related arthritis is often nonerosive, meaning it does not cause erosion of the bone. This distinguishes it from other types of arthritis like rheumatoid arthritis, which is erosive.
A patient with SLE complains of joint pain, diffuse swelling, and stiffness. Which of the following complications is this patient at increased risk for?
a. Bone loss and fracture
b. Muscle hypertrophy
c. Hypercalcemia
d. Anemia
a. Bone loss and fracture
Rationale: Patients with SLE have an increased risk for bone loss and fracture due to the chronic inflammation and possible use of corticosteroids in their treatment regimen.
What is a common early symptom of musculoskeletal problems in patients with systemic lupus erythematosus (SLE)?
a. Weight gain
b. Skin rash
c. Polyarthralgia
d. Hypertension
c. Polyarthralgia
Rationale: Polyarthralgia, or pain in multiple joints, is a common early symptom of musculoskeletal problems in patients with SLE. It often presents with morning stiffness and may precede other multisystem symptoms.
A patient with SLE presents with deformities in their fingers that include a swan neck appearance. What is the most likely diagnosis for this patient’s condition?
a. Rheumatoid arthritis
b. Osteoarthritis
c. SLE-related arthritis
d. Psoriatic arthritis
c. SLE-related arthritis
Rationale: The deformities described, including the swan neck appearance of the fingers, are characteristic of SLE-related arthritis. These deformities occur due to joint and muscle pain, stiffness, and nonerosive arthritis associated with SLE.
Which of the following symptoms in a patient with systemic lupus erythematosus (SLE) suggests the presence of lung disease?
a. Bradycardia and chest pain
b. Tachypnea and cough
c. Hypertension and fever
d. Edema and night sweats
b. Tachypnea and cough
Rationale: Tachypnea (rapid breathing) and cough suggest the presence of lung disease in patients with SLE. These symptoms indicate possible involvement of the respiratory system.
What cardiac complications may arise in systemic lupus erythematosus (SLE) due to fibrosis of the sinoatrial and atrioventricular nodes?
a. Dysrhythmias
b. Bradycardia
c. Atrial fibrillation
d. Ventricular tachycardia
a. Dysrhythmias
Rationale: Fibrosis of the sinoatrial and atrioventricular nodes in patients with SLE can lead to dysrhythmias. Dysrhythmias are indicative of abnormal heart rhythms and can be a sign of advanced disease.
A patient with SLE presents with inflammation of the heart lining, causing chest pain. Which of the following conditions is the patient most likely experiencing?
a. Pericarditis
b. Myocarditis
c. Endocarditis
d. Pleurisy
a. Pericarditis
Rationale: Inflammation of the heart lining is referred to as pericarditis, which can cause chest pain and other symptoms. It is one of the possible cardiac complications in patients with SLE.
What is a leading cause of death among patients with systemic lupus erythematosus (SLE) related to cardiac involvement?
a. Myocardial infarction
b. Pulmonary embolism
c. Dysrhythmias due to fibrosis of the sinoatrial and atrioventricular nodes
d. Congestive heart failure
c. Dysrhythmias due to fibrosis of the sinoatrial and atrioventricular nodes
Rationale: Dysrhythmias due to fibrosis of the sinoatrial and atrioventricular nodes show advanced disease and are a leading cause of death among patients with SLE.
A patient with SLE is being treated with corticosteroids and presents with high blood pressure and elevated cholesterol levels. What complications should be carefully monitored in this patient?
a. Hyperglycemia and weight loss
b. Hypotension and bradycardia
c. Hypertension and hypercholesterolemia
d. Anemia and leukopenia
c. Hypertension and hypercholesterolemia
Rationale: Hypertension and hypercholesterolemia from steroid use need aggressive treatment and careful monitoring in patients with SLE. These complications can increase the risk of cardiovascular disease.
Which of the following conditions are associated with secondary antiphospholipid syndrome (APS) in patients with SLE? (SATA)
a. Stroke
b. Gangrene
c. Heart attack
d. Deep vein thrombosis
a. Stroke
b. Gangrene
c. Heart attack
Rationale: Secondary antiphospholipid syndrome (APS) is a coagulation disorder that causes clots in the arteries and veins, increasing the risk for stroke, gangrene, and heart attack.
What is the main complication of hypertension and hypercholesterolemia in patients with SLE that requires careful monitoring?
a. Congestive heart failure
b. Peripheral neuropathy
c. Increased risk for cardiovascular disease
d. Renal failure
c. Increased risk for cardiovascular disease
Rationale: Hypertension and hypercholesterolemia in patients with SLE increase the risk for cardiovascular disease, making it important to manage these conditions aggressively and monitor the patient closely.
A 28-year-old female with a 3-year history of systemic lupus erythematosus (SLE) presents to the clinic with complaints of swelling in her lower extremities and foamy urine. The nurse reviews her laboratory results and notes 3+ proteinuria and an increased serum creatinine level. Based on the patient’s history and symptoms, which of the following interventions is the priority?
a. Initiate fluid restriction to prevent fluid overload
b. Educate the patient about dietary potassium restrictions
c. Prepare the patient for a possible renal biopsy
d. Discontinue all immunosuppressive therapy to prevent further renal damage
c. Prepare the patient for a possible renal biopsy
Rationale: In SLE, renal involvement can manifest as lupus nephritis, which varies in severity from mild proteinuria to rapidly progressive glomerulonephritis. A renal biopsy helps determine the extent of renal damage and guides treatment. While fluid and dietary management may be important, they do not replace the need for a definitive diagnosis through biopsy. Immunosuppressive therapy is crucial in slowing disease progression and should not be discontinued abruptly.
A patient with lupus nephritis is prescribed belimumab (Benlysta). Which statement by the patient indicates a need for further teaching?
a. “This medication helps reduce autoantibody levels and inflammation in my kidneys.”
b. “I should avoid live vaccines while taking this medication.”
c. “I may begin to feel better within a few days of starting the medication.”
d. “I should report any signs of infection, such as fever or chills, to my provider immediately.”
c. “I may begin to feel better within a few days of starting the medication.”
Rationale: Belimumab (Benlysta) is a human monoclonal antibody that reduces autoantibody levels and controls disease activity in lupus nephritis. However, it takes weeks to months for the full therapeutic effects to become evident. Patients should avoid live vaccines due to immunosuppression and be vigilant about infections, as the medication increases the risk of opportunistic infections.
A nurse is reviewing the medication list for a patient with lupus nephritis. Which of the following medications should the nurse question?
a. Azathioprine
b. Voclosporin
c. Prednisone
d. Ibuprofen
d. Ibuprofen
Rationale: NSAIDs like ibuprofen can worsen renal function in patients with lupus nephritis by reducing renal blood flow and contributing to nephrotoxicity. Immunosuppressive agents such as azathioprine, voclosporin, and corticosteroids like prednisone are commonly used to manage lupus nephritis and preserve renal function.
A 34-year-old woman with SLE is diagnosed with rapidly progressive glomerulonephritis. The provider prescribes high-dose IV methylprednisolone. What is the primary rationale for this treatment?
a. To provide immediate immunosuppression to reduce renal inflammation
b. To prevent osteoporosis and bone loss associated with lupus
c. To enhance renal perfusion and promote diuresis
d. To counteract potential drug interactions with belimumab
a. To provide immediate immunosuppression to reduce renal inflammation
Rationale: High-dose IV methylprednisolone is often used in lupus nephritis to rapidly reduce inflammation and immune-mediated damage in the kidneys. It is particularly beneficial in severe cases or when cytotoxic agents have not yet taken effect. It does not directly enhance renal perfusion or prevent osteoporosis.
A patient with lupus nephritis is started on voclosporin (Lupkynis). Which assessment finding would require immediate intervention?
a. Blood glucose level of 180 mg/dL
b. Blood pressure of 150/90 mmHg
c. Potassium level of 3.6 mEq/L
d. White blood cell count of 7,000/mm³
b. Blood pressure of 150/90 mmHg
Rationale: Voclosporin is a calcineurin inhibitor that can cause hypertension. Uncontrolled hypertension can accelerate renal damage in lupus nephritis, making it a priority concern. While hyperglycemia is a possible side effect, the blood glucose level provided is not immediately critical. The potassium and WBC levels are within normal limits.
A patient with lupus nephritis asks why they need immunosuppressive therapy. Which response by the nurse is most appropriate?
a. “These medications prevent infections that can worsen your kidney disease.”
b. “They help reduce your immune system’s attack on your kidneys.”
c. “They help your kidneys produce more urine to prevent fluid overload.”
d. “They work by reversing the kidney damage caused by lupus.”
b. “They help reduce your immune system’s attack on your kidneys.”
Rationale: In lupus nephritis, the immune system mistakenly attacks kidney tissue, leading to inflammation and damage. Immunosuppressive agents slow this process and help preserve kidney function. They do not directly prevent infections, increase urine output, or reverse kidney damage.
A nurse is providing discharge teaching to a patient with lupus nephritis who is prescribed azathioprine. Which statement by the patient indicates an understanding of the teaching?
a. “I should take this medication with food to decrease nausea.”
b. “I can stop taking this medication if I feel better.”
c. “I should limit my fluid intake to prevent fluid retention.”
d. “This medication will help repair my kidneys completely.”
a. “I should take this medication with food to decrease nausea.”
Rationale: Azathioprine can cause gastrointestinal discomfort, so taking it with food may help. It should not be discontinued abruptly, fluid intake should not be restricted unless directed by a provider, and it does not fully reverse kidney damage.
A nurse is monitoring a patient with lupus nephritis for signs of end-stage renal disease (ESRD). Which of the following findings would be most concerning?
a. Serum creatinine of 1.2 mg/dL
b. Blood pressure of 120/80 mmHg
c. Hemoglobin level of 14 g/dL
d. Urine output of 100 mL in 12 hours
d. Urine output of 100 mL in 12 hours
Rationale: Oliguria (low urine output) is a key indicator of worsening renal function and possible ESRD. A creatinine level of 1.2 mg/dL and normal hemoglobin and BP levels are not immediately concerning in this context.
A patient with lupus nephritis is prescribed prednisone. Which of the following statements by the patient requires immediate intervention?
a. “I will take my prednisone dose in the morning with food.”
b. “I will check my blood glucose regularly since this medication can raise it.”
c. “I will stop taking my prednisone if I feel better to avoid side effects.”
d. “I will notify my provider if I develop any signs of infection.”
c. “I will stop taking my prednisone if I feel better to avoid side effects.”
Rationale: Abruptly stopping corticosteroids can lead to adrenal insufficiency and a lupus flare. Patients must taper the dose under medical supervision.
A patient with lupus nephritis asks about the long-term prognosis of their kidney disease. The nurse should base the response on which key fact?
a. “Kidney involvement in lupus is rare and not a major concern.”
b. “With proper treatment, progression to end-stage renal disease can often be slowed or prevented.”
c. “Most patients with lupus nephritis require immediate dialysis.”
d. “Your kidney function will return to normal with immunosuppressive therapy.”
b. “With proper treatment, progression to end-stage renal disease can often be slowed or prevented.”
Rationale: While lupus nephritis can lead to ESRD, early and aggressive treatment can slow its progression. Immediate dialysis is not required in most cases, and complete reversal of damage is not guaranteed.